Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients.
作者信息
Del Bello Arnaud, Marion Olivier, Vellas Camille, Faguer Stanislas, Izopet Jacques, Kamar Nassim
机构信息
Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France.
INFINITY- Inserm U1291-CNRS U5051, Toulouse, France.
出版信息
Transplantation. 2021 Oct 1;105(10):e146-e147. doi: 10.1097/TP.0000000000003883.
Abstract
摘要
相似文献
1
Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients.实体器官移植患者中的抗SARS-CoV-2单克隆抗体
Transplantation. 2021 Oct 1;105(10):e146-e147. doi: 10.1097/TP.0000000000003883.
2
Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.SARS-CoV-2 疫苗接种后突破 COVID-19 在实体器官移植受者中的发生：症状病例分析和单克隆抗体治疗。
Transpl Infect Dis. 2022 Apr;24(2):e13779. doi: 10.1111/tid.13779. Epub 2022 Jan 31.
3
Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients.卡西瑞维单抗-英夫西单抗预防实体器官移植受者感染严重急性呼吸综合征冠状病毒2
Transplantation. 2022 May 1;106(5):e275-e276. doi: 10.1097/TP.0000000000004087. Epub 2022 Mar 8.
4
Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.用于预防和治疗实体器官移植受者2019冠状病毒病的抗刺突单克隆抗体。
Curr Opin Organ Transplant. 2022 Aug 1;27(4):269-276. doi: 10.1097/MOT.0000000000000981.
5
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience.索托维单抗治疗实体器官移植患者早期轻/中度严重急性呼吸综合征冠状病毒2感染：单中心经验
Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.
6
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
7
Letter to the editor: "hook" (prozone) effect in sars-cov-2 anti-spike binding antibody levels following vaccination, infection, or monoclonal antibody in solid organ transplant recipients.给编辑的信：在实体器官移植受者中，接种疫苗、感染或使用单克隆抗体后，SARS-CoV-2 刺突结合抗体水平的“钩（前区）”效应。
Clin Transplant. 2023 Aug;37(8):e15044. doi: 10.1111/ctr.15044. Epub 2023 Jun 17.
8
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?新冠疫情能否改善实体器官移植受者的管理？
Viruses. 2022 Aug 24;14(9):1860. doi: 10.3390/v14091860.
9
Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update.实体器官移植受者对第四剂SARS-CoV-2疫苗的抗体反应：最新情况
Transplantation. 2022 Jul 1;106(7):e338-e340. doi: 10.1097/TP.0000000000004137. Epub 2022 Apr 15.
10
Comment on "Re-infection with SARS-CoV-2 in solid-organ transplant recipients".关于“实体器官移植受者再次感染严重急性呼吸综合征冠状病毒2”的评论
Transpl Infect Dis. 2022 Jun;24(3):e13838. doi: 10.1111/tid.13838. Epub 2022 Apr 25.
引用本文的文献
1
Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients.实体器官移植受者应用单克隆抗体治疗 COVID-19 的临床经验。
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):25-28. doi: 10.37201/req/s01.07.2023. Epub 2023 Nov 24.
2
The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.中和单克隆抗体在 COVID-19 轻症至中度移植受者中的疗效。
Transpl Immunol. 2023 Apr;77:101777. doi: 10.1016/j.trim.2022.101777. Epub 2022 Dec 28.
3
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?新冠疫情能否改善实体器官移植受者的管理？
Viruses. 2022 Aug 24;14(9):1860. doi: 10.3390/v14091860.
4
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.接受替沙格韦单抗-西加韦单抗预防的免疫功能低下患者中早发性严重急性呼吸综合征冠状病毒2感染的特征
Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.
5
Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: A meta-analysis.单克隆抗体疗法可改善器官移植受者新冠肺炎的严重程度和死亡率：一项荟萃分析。
J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.027. Epub 2022 Jul 1.
6
Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients.新冠感染实体器官移植受者临床护理的演变
Curr Transplant Rep. 2022;9(3):185-198. doi: 10.1007/s40472-022-00368-z. Epub 2022 May 31.
7
COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus.免疫功能低下宿主中的 COVID-19，包括人类免疫缺陷病毒感染者。
Infect Dis Clin North Am. 2022 Jun;36(2):397-421. doi: 10.1016/j.idc.2022.01.006. Epub 2022 Feb 1.
8
Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series.针对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta和Omicron变异株的肾移植受者的单克隆抗体治疗：一项单中心病例系列研究
Kidney Med. 2022 Jun;4(6):100470. doi: 10.1016/j.xkme.2022.100470. Epub 2022 Apr 27.
9
Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2.索托维单抗在儿童中的早期应用：一名感染新冠病毒的11岁肾移植受者的病例报告
Children (Basel). 2022 Mar 23;9(4):451. doi: 10.3390/children9040451.
10
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients.肾或肾胰联合移植受者中 SARS-CoV-2 中和单克隆抗体的初步经验。
Transpl Int. 2022 Mar 31;35:10109. doi: 10.3389/ti.2022.10109. eCollection 2022.
Zotero 插件